North Chicago, IL – February 20, 2026 – In a significant advancement for the treatment of chronic lymphocytic leukemia (CLL), the U.S. Food and Drug Administration (FDA) has approved a combination therapy of Venclexta (venetoclax) and Calquence (acalabrutinib) for adult patients newly diagnosed with the disease. This approval marks the first all-oral, fixed-duration combination regimen for this patient population, offering a potentially transformative approach to managing CLL and providing a new option for those seeking treatment. The decision, announced today by AbbVie, is based on data from the Phase 3 AMPLIFY trial, which demonstrated promising results in terms of progression-free survival.
CLL, a type of cancer that affects the blood and bone marrow, is often slow-growing but can turn into aggressive over time. Traditional treatments have often involved lengthy chemotherapy regimens with significant side effects. This new combination therapy offers a different path, aiming to provide effective treatment with a defined duration, potentially allowing patients to achieve periods of remission and improve their quality of life. The approval addresses a critical require for more targeted and manageable treatment options for individuals facing a new CLL diagnosis.
The approval represents a collaborative effort between AbbVie and AstraZeneca, the manufacturers of Venclexta and Calquence, respectively. Svetlana Kobina, vice president of global medical affairs, oncology at AbbVie, hailed the FDA decision as a “significant milestone” for the company and, more importantly, for people living with CLL. “As the first and only all-oral, fixed-duration combination regimen for previously untreated patients, the Venclexta plus acalabrutinib approval expands choice and flexibility for patients and providers navigating complex treatment decisions in CLL,” she stated in a press release. Dave Fredrickson, executive vice president of hematologic oncology at AstraZeneca, echoed this sentiment, noting the combination’s potential to “transform” first-line treatment decisions for CLL.
Understanding the AMPLIFY Trial and its Results
The FDA’s approval is rooted in the findings of the Phase 3 AMPLIFY trial, a global, multi-center study evaluating Venclexta plus acalabrutinib, either alone or in combination with obinutuzumab, against chemoimmunotherapy (investigator’s choice of fludarabine-cyclophosphamide-rituximab [FCR] or bendamustine-rituximab [BR]). The trial focused on patients with previously untreated CLL who did not have a specific genetic abnormality, del (17p), or a TP53 mutation.
While detailed results are still being analyzed and presented at medical conferences, initial data indicates a significant benefit for patients receiving the Venclexta and Calquence combination. AstraZeneca highlighted that patients treated with the combination experienced prolonged progression-free survival compared to those receiving standard chemotherapy. Specifically, the company reported that patients on the combination were “without progression of the disease at three years, compared to 67% of patients treated with standard chemotherapy.” the median progression-free survival had not been reached for the combination group, compared to 47.6 months for chemoimmunotherapy. AstraZeneca too stated that the combination reduced the risk of disease progression or death by 35% compared to the standard treatment.
How Venclexta and Calquence Work
Venclexta (venetoclax) is a BCL-2 inhibitor, a targeted therapy that works by blocking a protein called BCL-2, which helps cancer cells survive. By inhibiting BCL-2, Venclexta triggers programmed cell death (apoptosis) in leukemia cells. Calquence (acalabrutinib), is a Bruton’s tyrosine kinase (BTK) inhibitor. BTK is a protein that plays a crucial role in the survival and growth of B cells, including the cancerous B cells found in CLL. By blocking BTK, Calquence disrupts the signaling pathways that promote cancer cell proliferation.
The combination of these two targeted therapies offers a synergistic effect, attacking CLL cells through different mechanisms. This dual approach aims to maximize treatment efficacy while potentially minimizing the side effects often associated with traditional chemotherapy. The all-oral nature of the regimen also represents a significant convenience for patients, eliminating the need for frequent intravenous infusions.
Implications for CLL Treatment and Future Research
This FDA approval is expected to reshape the treatment landscape for CLL, particularly for patients who are suitable candidates for a fixed-duration, all-oral regimen. The availability of this new option provides clinicians with greater flexibility in tailoring treatment plans to individual patient needs and preferences. The fixed-duration aspect of the therapy is also noteworthy, as it offers the potential for patients to complete treatment and potentially achieve long-term remission, rather than continuing therapy indefinitely.
The approval also underscores the growing trend towards targeted therapies in cancer treatment. By focusing on specific molecular targets within cancer cells, these therapies aim to minimize damage to healthy cells and reduce the severity of side effects. Further research is ongoing to explore the potential of Venclexta and Calquence in other hematologic malignancies and to identify biomarkers that can predict which patients are most likely to benefit from this combination therapy. The AMPLIFY trial continues to be monitored for long-term outcomes and to assess the durability of the responses observed in patients treated with the Venclexta and Calquence combination.
What Patients Should Know
Patients newly diagnosed with CLL should discuss the potential benefits and risks of this new combination therapy with their hematologist-oncologist. It’s important to understand that not all patients are suitable candidates for this treatment, and individual factors will influence treatment decisions. The FDA’s approval provides a valuable new tool in the fight against CLL, but it’s crucial for patients to have a thorough understanding of their options and to work closely with their healthcare team to develop a personalized treatment plan.
The availability of Venclexta and Calquence may vary depending on geographic location and insurance coverage. Patients should check with their insurance provider to determine their coverage for these medications. Additional information about CLL and available treatment options can be found on the websites of organizations such as the Leukemia & Lymphoma Society (https://www.lls.org/) and the National Cancer Institute (https://www.cancer.gov/).
The market reacted positively to the news, with AbbVie’s stock showing a slight increase of 0.1% to $224.61 before market open in New York on Friday morning, and AstraZeneca rising 0.4% to 15,344.40 pence in London. These movements reflect investor confidence in the potential of this new treatment to generate significant revenue and improve patient outcomes.
Looking ahead, AbbVie and AstraZeneca will continue to monitor the performance of Venclexta and Calquence in real-world clinical practice and to explore opportunities to expand the use of this combination therapy to other patient populations. The companies are also committed to investing in research and development to discover new and innovative treatments for CLL and other blood cancers.
Next Steps: AbbVie and AstraZeneca are expected to present further detailed results from the AMPLIFY trial at upcoming medical conferences throughout 2026. Clinicians will be closely evaluating these data to refine treatment guidelines and optimize the use of this new combination therapy. Patients are encouraged to discuss this approval with their healthcare providers to determine if it is a suitable treatment option for their individual circumstances.
Do you have questions about the new CLL treatment? Share your thoughts and experiences in the comments below. Please also share this article with anyone who may benefit from this information.
Keep reading